文献速递肝胆胰外科胃肠外科围术期管理与 ERAS

结直肠癌肝转移肝切除围术期循环肿瘤DNA动态变化的前瞻性研究

Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases.
PubMed 文献 · Ann Surg · 2022-07-06

该前瞻性研究纳入48例接受根治性肝切除的结直肠癌肝转移患者,评估围术期ctDNA动态与预后的关联。中位随访55个月,ctDNA术前术后均阳性者无复发生存期最差(中位6.0个月),而术前阳性术后转阴者预后显著改善(HR 0.24)。围术期ctDNA动态可识别高复发风险患者,或可指导治疗决策与术后监测。

要点

  • 肝切除术前术后ctDNA均阳性者复发风险最高(中位RFS 6.0个月,P=0.001)
  • 术前阳性术后转阴者较持续阳性者RFS和OS均显著改善(HR均为0.24)
  • 组织体细胞突变与生存无显著关联,围术期ctDNA动态更具预后价值

核心结论

  • 围术期ctDNA动态与结直肠癌肝转移肝切除患者生存相关,可识别高复发风险患者,或可指导治疗决策与术后监测。

研究设计与样本

  • 前瞻性研究纳入48例2013-2017年接受术前化疗后根治性肝切除的结直肠癌肝转移患者,采用血浆-only检测分析肝切除前与术后配对ctDNA,中位随访55个月。

主要发现

  • ctDNA术前术后均阳性14例(29%),术前阳性术后阴性19例(40%),均阴性11例(23%)。
  • ctDNA+/+组中位RFS为6.0个月,ctDNA+/-组未达到,ctDNA-/-组为33.0个月(P=0.001)。
  • 与ctDNA+/+相比,ctDNA+/-的RFS改善(HR 0.24,95%CI 0.1-0.58),OS亦改善(HR 0.24,95%CI 0.08-0.74)。
  • 组织体细胞突变(TP53 54%、RAS 48%、SMAD4 10%、FBXW7 6%、BRAF 4%)与生存无显著关联。
  • 校正术前化疗、同时性病变和≥2个肝转移灶后,ctDNA+/-(HR 0.21,95%CI 0.08-0.53)和ctDNA-/-(HR 0.21,95%CI 0.08-0.56)均独立关联RFS改善。

临床怎么用

  • 对结直肠癌肝转移肝切除患者,可考虑围术期ctDNA动态检测以辅助复发风险分层。
  • 术前ctDNA阳性而术后转阴者预后较好,持续阳性者需加强术后监测与治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the association of perioperative ctDNA dynamics on outcomes after hepatectomy for CLM. SUMMARY BACKGROUND DATA: Prognostication is imprecise for patients undergoing hepatectomy for CLM, and ctDNA is a promising biomarker. However, clinical implications of perioperative ctDNA dynamics are not well established. METHODS: Patients underwent curative-intent hepatectomy after preoperative chemotherapy for CLM (2013-2017) with paired prehepatectomy/postoperative ctDNA analyses via plasma-only assay. Positivity was determined using a proprietary variant classifier. Primary endpoint was recurrence-free survival (RFS). Median follow-up was 55 months. RESULTS: Forty-eight patients were included. ctDNA was detected before and after surgery (ctDNA+/+) in 14 (29%), before but not after surgery (ctDNA+/-) in 19 (40%), and not at all (ctDNA-/-) in 11 (23%). Adverse tissue somatic mutations were detected in TP53 (n = 26; 54%), RAS (n = 23; 48%), SMAD4 (n = 5; 10%), FBXW7 (n = 3; 6%), and BRAF (n = 2; 4%). ctDNA+/+ was associated with worse RFS (median: ctDNA+/+, 6.0 months; ctDNA+/-, not reached; ctDNA-/-, 33.0 months; P = 0.001). Compared to ctDNA+/+, ctDNA+/- was associated with improved RFS [hazard ratio (HR) 0.24 (95% confidence interval (CI) 0.1-0.58)] and overall survival [HR 0.24 (95% CI 0.08-0.74)]. Adverse somatic mutations were not associated with survival. After adjustment for prehepatectomy chemotherapy, synchronous disease, and ≥2 CLM, ctDNA+/- and ctDNA-/- were independently associated with improved RFS compared to ctDNA+/+ (ctDNA+/-: HR 0.21, 95% CI 0.08-0.53; ctDNA-/-: HR 0.21, 95% CI 0.08-0.56). CONCLUSIONS: Perioperative ctDNA dynamics are associated with survival, identify patients with high recurrence risk, and may be used to guide treatment decisions and surveillance after hepatectomy for patients with CLM.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Newhook TE, Overman MJ, Chun YS, et al. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Ann Surg. 2022. PMID: 35797554. doi:10.1097/SLA.0000000000005461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。